Jpmorgan Chase & CO Zai Lab LTD Call Options Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ZLAB
# of Institutions
121Shares Held
46.7MCall Options Held
223KPut Options Held
588K-
Janus Henderson Group PLC London, X08.76MShares$232 Million0.11% of portfolio
-
Wellington Management Group LLP Boston, MA8.44MShares$223 Million0.04% of portfolio
-
Capital World Investors Los Angeles, CA6.44MShares$170 Million0.02% of portfolio
-
Viking Global Investors LP1.95MShares$51.5 Million0.18% of portfolio
-
Bamco Inc New York, NY1.91MShares$50.4 Million0.13% of portfolio
About Zai Lab Ltd
- Ticker ZLAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,908,704
- Market Cap $2.59B
- Description
- Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...